Stock of the Day: How Analysts Feel About Esperion Therapeutics Inc After Today’s Huge Decline?

Stock of the Day: How Analysts Feel About Esperion Therapeutics Inc After Today's Huge Decline?

The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) is a huge mover today! About 165,334 shares traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 15.90% since March 11, 2016 and is downtrending. It has underperformed by 21.36% the S&P500.
The move comes after 5 months negative chart setup for the $294.33M company. It was reported on Oct, 14 by Barchart.com. We have $10.63 PT which if reached, will make NASDAQ:ESPR worth $41.21M less.

Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on November, 3. They expect $-0.88 EPS, down 54.39% or $0.31 from last year’s $-0.57 per share. After $-0.62 actual EPS reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.

Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage

Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. Esperion Therapeutics has been the topic of 30 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets on Tuesday, December 15 with “Outperform”. As per Monday, August 31, the company rating was maintained by Chardan Capital Markets. Lake Street maintained the stock with “Buy” rating in Wednesday, June 29 report. Needham upgraded the shares of ESPR in a report on Wednesday, August 19 to “Strong Buy” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, June 29. The company was maintained on Thursday, June 30 by Needham. Barclays Capital maintained it with “Overweight” rating and $28 target price in Wednesday, February 24 report. On Friday, November 6 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Wednesday, June 29 the stock rating was downgraded by Barclays Capital to “Equal-Weight”. The firm earned “Sell” rating on Monday, July 27 by Chardan Capital Markets.

According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”

Insitutional Activity: The institutional sentiment increased to 1.27 in 2016 Q2. Its up 0.11, from 1.16 in 2016Q1. The ratio improved, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Blackrock Fund Advisors owns 657,919 shares or 0% of their US portfolio. Stifel Financial Corporation reported 15,017 shares or 0% of all its holdings. Gam Ag, a Switzerland-based fund reported 128,000 shares. Moreover, Tfs Capital Lc has 0.05% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 26,510 shares. Teachers Advsr holds 21,380 shares or 0% of its portfolio. Granahan Mngmt Ma, a Massachusetts-based fund reported 248,030 shares. Tiverton Asset Management Ltd Llc accumulated 0.12% or 56,063 shares. Great West Life Assurance Can owns 1,300 shares or 0% of their US portfolio. Vanguard Gru holds 0% or 811,704 shares in its portfolio. Citigroup Inc last reported 0% of its portfolio in the stock. Northern last reported 0% of its portfolio in the stock. Moreover, Amer Group has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 8,240 shares. Blackrock, a New York-based fund reported 3,401 shares. Moreover, Pnc Fincl Svcs Grp has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 71 shares. Commercial Bank Of America De last reported 0% of its portfolio in the stock.

More recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Fool.com which released: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” on June 29, 2016. Also Benzinga.com published the news titled: “10 Biggest Price Target Changes For Friday” on October 14, 2016. Fool.com‘s news article titled: “Why Esperion Therapeutics, Inc. Stock Cratered Today” with publication date: September 29, 2015 was also an interesting one.

ESPR Company Profile

Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment